Status:
COMPLETED
Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Overweight
Obesity
Eligibility:
FEMALE
18-65 years
Phase:
PHASE1
Brief Summary
The study looks at how the study medicine affects the level in the blood of a birth control pill. The study also looks at how the study medicine affects the duration of emptying of the stomach. Partic...
Eligibility Criteria
Inclusion
- Female of non-childbearing potential, aged 18-65 years (both inclusive) at the time of signing informed consent.
- Body mass index (BMI) between 25.0 and 39.9 kg/m\^2 (both inclusive). Overweight should be due to excess adipose tissue, as judged by the investigator.
Exclusion
- Known or suspected hypersensitivity to trial products (including acetaminophen) or related products.
- Previous participation in this trial. Participation is defined as signed informed consent.
- Previous participation in trial(s) with NNC0174-0833 unless documented that the subject was assigned to placebo treatment. Participation is defined as randomised.
- Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
Key Trial Info
Start Date :
September 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 6 2020
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04074174
Start Date
September 12 2019
End Date
March 6 2020
Last Update
January 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Montreal, Quebec, Canada, H3P 3P1